Brief analysis of China's foreign trade of pharmaceutical products from January to April 2022

a brief analysis of China's foreign trade of pharmaceutical products from January to April 2022, and the export volume and price of drugs rose at the same time

CPHI world pharmaceutical raw materials China Exhibition

Since 2022, the global COVID-19 has continued to rage, the conflict between Russia and Ukraine has frustrated the slow recovery of the global economy, commodity prices have risen sharply, inflationary pressures and supply chain pressures have continued to increase, and the recovery of Global trade is under pressure. At the same time, the domestic epidemic occurred frequently, which put great pressure on the production and operation of some enterprises and the stability of the supply chain. In this case, with the implementation of a series of stable foreign trade policies and the support of the inherent advantages of China's pharmaceutical industry chain, the foreign trade of pharmaceutical products has maintained a steady development.

The volume and price of drug exports rose at the same time, and the export of devices fell as a whole

From January to April 2022, the export volume of traditional Chinese medicine products from January to April was 1.83 billion US dollars, an increase of 21.2% year on year; The export volume was 127500 tons, an increase of 4% year-on-year; The average export price increased by 16.2% year-on-year. In terms of segmented products, the export of plant extracts with the highest proportion continued to maintain a high growth rate, with exports of US $1.18 billion from January to April, an increase of 28.5% year-on-year; The export of Chinese herbal medicines and decoction pieces was US $400million, a year-on-year decrease of 3%, mainly due to the decline in the average export price; The export of Chinese patent medicine was US $150million, with a year-on-year increase of 45.7%; The export of health products was US $110million, an increase of 21.6% year-on-year.

From January to April, the export volume of China's western medicine products was 22.21 billion US dollars, an increase of 20.6% year-on-year; The export volume was 4.119 million tons, with a year-on-year increase of 16.9%; The average export price increased by 3.3% year-on-year.

As a competitive product of China's pharmaceutical industry, the export performance of Western medicine APIs has been extremely excellent this year: the export volume from January to April was US $17.58 billion, a substantial increase of 37.9% year-on-year; The export volume was 4.115 million tons, with a year-on-year increase of 17.6%; The average export price increased by 17.3% year-on-year.

In terms of segmented products, the export of most bulk drugs has increased to varying degrees: the export volume of anti epidemic related categories such as antipyretics and analgesics, cephalosporins and penicillins increased by more than 10%, 28.6%, 15% and 13.8% respectively; the export volume of hormones, anti infectives and vitamins increased by 8.8%, 7.4% and 2.4% respectively, and the export volume of tetracyclines decreased by 14.3% year-on-year; The export volume of many varieties of non anti epidemic bulk drugs increased significantly year-on-year, such as the export volume of central nervous system and cardiovascular system doubled year-on-year, and the export volume of amino acids and anesthesia increased by 60.2% and 46.7% respectively.

From January to April, the export of Western medicine preparations was US $2.24 billion, a year-on-year increase of 25.8%, the export volume increased by 4.2% year-on-year, and the average export price increased by 20.7% year-on-year. Among them, the export volume of hormone preparations increased by 103.8%, mainly driven by the substantial growth of insulin preparations; The export volume of penicillin preparations increased by 25% year-on-year, cephalosporins remained the same year-on-year, and other Xicheng drugs increased by 9.1% year-on-year.

The export volume of biochemical drugs was 2.39 billion US dollars, a year-on-year decrease of 38.4%, the export volume increased by 11.1% year-on-year, and the average export price decreased by 44.6%. It was mainly caused by the sharp decline in the export volume of human vaccines, which fell by 72.8% from January to April this year.

From January to April, China's exports of medical devices reached 31.27 billion US dollars, a year-on-year decrease of 9.6%. The export of protective medical dressings such as masks (medical / non-medical) and protective clothing continued to decline significantly. From January to April, the export of medical dressings was $2.97 billion, a year-on-year decrease of 58.5%; At the same time, the export of disposable consumables also showed a downward trend. From January to April, the export value of disposable consumables was US $10.11 billion, a year-on-year decrease of 18.6%. From January to April, the export of new crown testing products reached US $8.33 billion, a year-on-year increase of 38%, maintaining a rapid growth trend

Excellent performance in emerging markets, RCEP brings new impetu

From January to April 2022, China's pharmaceutical products were exported to the EU by US $11.96 billion, a year-on-year decrease of 7%, and imports from the EU were US $12.98 billion, basically flat year-on-year; Exports to the United States were US $10.18 billion, a year-on-year decrease of 11.2%, and imports from the United States were US $4.63 billion, a year-on-year decrease of 4.5%; Exports to "the Belt and Road" countries and regions reached US $18.11 billion, a year-on-year increase of 5.1%, exports from "the Belt and Road" emerging markets accounted for 32.8%, and imports from "the the Belt and Road" countries and regions reached US $5.12 billion, a year-on-year increase of 6.7%.